InvestLog
Back to Market返回行情

CERO CERo Therapeutics Holdings, Inc.

OTCHealthcare
$0.0170+61.90%ClosedMarket Cap: $20,491

As of 2026-07-09 16:00

Why CERO matters now

CERo Therapeutics Holdings, Inc. (CERO) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.02 with +61.90% on the session and $20.5K in market capitalization.

The latest indexable market news headline is "CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment" from GlobeNewsWire.

Latest News

CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentGlobeNewsWire · 2026-06-15
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentGlobe News Wire · 2026-06-15
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 TrialGlobeNewsWire · 2026-05-11
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 TrialGlobe News Wire · 2026-05-11
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 TrialGlobeNewsWire · 2026-04-14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

OTC

Beta

0.16

CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.